Stuart Bell Profile
Stuart Bell

@InceptuaAccess

Followers
47
Following
44
Media
6
Statuses
97

Executive Vice President - Inceptua Early Access.

Windsor, England
Joined September 2017
Don't wanna be here? Send us removal request.
@InceptuaAccess
Stuart Bell
2 years
Inceptua Early Access will be participating in @BiotechWkBoston from 18-21 September. If you have an interest in Expanded Access, Early Access, Compassionate Use, or any other form of specialised medicine distribution, then please connect to meet up.
0
0
2
@rareanaemias
Rare Anaemias International Network
4 years
📣 September is #SickleCellAwarenessMonth! 📣 Patients with #sicklecelldisease have abnormal haemoglobin (called haemoglobin S), which can change red blood cells into a sickle or crescent shape. Help increase awareness and share this post! @SCDAAorg @SickleCellUK #rarenaemias
0
9
11
@InceptuaAccess
Stuart Bell
5 years
Across Europe there is disparity in the average time for new drugs to be approved and accessible to patients. For an orphan drug, the delay between centralised European Medicines Agency approval and in-country commercial availabi… https://t.co/RuNy99aWLa
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
0
0
@InceptuaAccess
Stuart Bell
5 years
Given the current focus on #preapproval access due to COVID-19, we thought this would be a good opportunity to review #preapproval access with industry expert @PaulAliu2000
Tweet card summary image
linkedin.com
Given the current focus on #preapproval access due to COVID-19, we thought this would be a good opportunity to review #preapproval access with industry expert @PaulAliu2000
0
1
1
@InceptuaAccess
Stuart Bell
6 years
Please do take a look at the webinar for some fantastic insights on #Preapproval access from @PaulAliu2000
@InceptuaGroup
Inceptua - Pharma Company and Service Partner
6 years
Access our latest webinar #ondemand https://t.co/6kl42nuWdz and learn more about #ExpandedAccess as a Key Component in the #Drugdevelopment and #Launch Process #preapprovalaccess
0
1
2
@InceptuaAccess
Stuart Bell
6 years
Great article, Neil! Something like this has been coming down the line for some time. Concerning for patients. Let's hope a pragmatic approach is taken. #preapprovalaccess #expandedaccess
linkedin.com
Great article, Neil! Something like this has been coming down the line for some time. Concerning for patients. Let's hope a pragmatic approach is taken. #preapprovalaccess #expandedaccess
0
0
0
@Medicine_Access
The Journal of Medicine Access
6 years
Patients and physicians are wanting access to approved orphan drugs but access can still take 12-18 months in some EU countries. @ME_Corbett @InceptuaGroup @orphan_drugs #WorldOrphanDrugCongress #MedicineAccess #MarketAccess
0
3
3
@InceptuaAccess
Stuart Bell
6 years
Looking forward to EA3 https://t.co/U6bXFdA3oT @Expanded_Access and discussing access to medicines with the leaders in this space.
@Expanded_Access
Expanded Access Summit
6 years
EA Summit Faculty member, @StuartBMAC on early access to #RareDisease treatment in Europe. #expandedaccess #clinicaltrials https://t.co/xcIYt70PDC
0
1
2
@InceptuaAccess
Stuart Bell
6 years
Uncharted waters: Navigating requests for experimental medicines https://t.co/OEPwATO4jA via @bcmhouston Pleased to see a focus on neuro-oncology in expanded access. Not sure I agree much with the issues around clinical trials and ethics though. But keen to follow developments.
blogs.bcm.edu
A closer look at the FDA's Expanded Access Program for investigational drugs and how physicians and patients navigate and manage the process.
1
0
0
@InceptuaAccess
Stuart Bell
7 years
11% of planned clinical trials fail to enrol a single patient. #rarediseasesummit
0
3
2
@InceptuaAccess
Stuart Bell
7 years
Best pre-approval conference by far. #expandedaccesssummit #expandedaccess
0
0
1
@Expanded_Access
Expanded Access Summit
7 years
Excellent piece on global #ExpandedAccess pathways by EA Summit faculty member, Dr. Stuart Bell. Hear him live at the annual event, Expanded Access 3.0, Jan. 27-29, 2020 in Washington DC.
0
1
0
@InceptuaAccess
Stuart Bell
7 years
Brilliant @JAMAOnc paper on single patient use #expandedaccess at @mskcc by Hyman et. al. 36.1% of products were in Phase 2, 39.4% in Phase 3, and an incredible 18.8% were in Phase 1. Authors call for routine prospective collection of efficacy data in expanded access. Fully agree
0
8
10
@InceptuaAccess
Stuart Bell
7 years
An exciting new service to allow pharma and biotech a 'safe harbor' to explore how #preapprovalaccess or #expandedaccess may work for them. No obligation. No pressure. Just impartial, expert advice. Free-of-charge.
0
0
0